Case Number:

IPR2021-01024

Case Type:

IPR

Status:

Terminated-Settled

Petitioner:

Fresenius Kabi USA, LLC

1. Filed: June 28, 2021 00:00

   Coverage

   1. January 07, 2022

      'Hypothetical' Suit Won't Shield Roche Patents From Review

      The Patent Trial and Appeal Board on Thursday instituted inter partes reviews of two patents on Roche unit Chugai's arthritis and COVID-19 monoclonal antibody drug Actemra, ruling that "hypothetical future district court litigation" over a biosimilar planned by Fresenius is no reason not to review the patents.

   ---

   Stay ahead of the curve

   In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

   
   

   • Search PTAB cases and full-text documents.
   • Download filings with the U.S. Patent & Trademark Office’s Patent Trial & Appeal Board.
   • Set up alerts on new cases, follow ongoing cases, track new decisions and so much more!

   TRY LAW360 FREE FOR SEVEN DAYS

   View the PTAB case documents

   Already a subscriber? Click here to login